Clay Siegall is the chairman of Seattle Genetics Inc. A Genetics Ph.D. graduate from George Washington University, Mr. Clay Siegall also holds a degree in Zoology. He won the Pierce Awards in 1995 and was a finalist of Ernest and Young’s Pacific Northwest AWARDS FOR THE Entrepreneur of the year.
Siegall founded Seattle Genetics and has been its chairman since 2004. Before becoming chairman, he held the Chief Executive officer position for fifteen years and the Presidential position for some 17 years. Prior to that, he was an Executive Vice President for a three year period and spent 4 years working at Bristol-Myers for the Squibb Pharmaceutical Research Institute where he was the Principal Scientist for 2 years. He has also been Ultragenyx Pharmaceutical’s chairman since 2014. His experience in cancer research and therapeutic drugs development stretches to over twenty years.
Siegall has also sat on the boards of various companies. These include being part of e board of Governors at Hutchison’s Cancer Research. He was a director at Alder Biopharmaceuticals for twelve years. Mr. Siegall is a former director at Washington Biotech and Biomedicine association and was non–executive director for 3 years at Mirna Therapeutics. From 1988-1991 he was part a fellow at National Cancer Institute and also at National Institute for Health. Finally, he sits on the boards of Scientific Counselors to Treatment Research Foundation.
He frequently writes journals and scientific papers, with 67 of these written by him so far. Mr. Siegall has patented nine different items to his name and sits on various scientific journals editorial boards. Through strategic partnerships, his company has generated $1.2 billion and made another $350 million from licensing its technology – Antibody Drugs Conjugates.
Targeted therapy is a type of gene testing that enables doctors to come up with customized treatment methods for cancer patients. This testing allows for the identification of genetic errors within the patient that may have already been treated effectively in another patient thus can be eliminated to reduce the risk of infections. Through his firm, Mr. Siegall hopes to develop drugs for targeted therapy which will help not only to eliminate cancerous cells before they spread but also prevent other diseases thus saving the lives of many.